HANSOH PHARMA(03692): Enters into a Strategic Collaboration and License Agreement with Roche

HANSOH PHARMA (03692) announced that on October 17, 2026, the Company's wholly-owned subsidiaries Shanghai Hansoh Biomedical Co., Ltd., Changzhou Hengbang Pharmaceutical Co., Ltd., and Hansoh Bio, LLC (collectively "Hansoh") entered into a strategic collaboration and license agreement with F. Hoffmann-La Roche Ltd (Roche). This strategic collaboration covers a portfolio consisting of a series of antibody-drug conjugate (ADC) programs, including two Hansoh preclinical ADC programs and multiple ADC programs directed at targets proposed by Roche and developed leveraging Hansoh's proprietary ADC technology platform. Under the collaboration agreement, Hansoh will lead the early development of such programs, up to the completion of global Phase Ia clinical trials. Roche will be responsible for further development of such programs worldwide (excluding Mainland China, Hong Kong, Macau, and Taiwan). Hansoh retains all rights to develop, register, and commercialize such programs in Mainland China, Hong Kong, Macau, and Taiwan. Hansoh will receive an upfront payment of US$400 million and a one-year anniversary payment of US$110 million, and will be eligible to receive potential milestone payments exceeding US$15 billion based on the development, regulatory, and commercialization progress of such programs, as well as tiered royalties based on future potential product sales. Under the collaboration agreement, Hansoh has the option to designate up to two programs and participate in their development outside Mainland China, Hong Kong, Macau, and Taiwan, and in return for such investment, will be eligible to receive additional proceeds from the commercialization of such two programs in the United States. F. Hoffmann-La Roche Ltd is a subsidiary of Roche Holding AG, which is listed on the SIX Swiss Exchange. Roche was founded in Basel, Switzerland in 1896 and is now a leading provider of transformative medicines and diagnostics to millions of people in more than 150 countries worldwide.